{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:25:33Z","timestamp":1792275933342,"version":"4.4.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:10:25Z","timestamp":1667956225000},"page":"303-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["PET\/CT in Hodgkin Lymphoma: An Update"],"prefix":"10.1053","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix M","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0001","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0002","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0003","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0004","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0007","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0008","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): A report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0010","author":"Hertzberg","year":"2015"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0011","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0012","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2967\/jnumed.114.145326","article-title":"Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma","volume":"55","author":"Carr","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0013","doi-asserted-by":"crossref","unstructured":"Duehrsen U, H\u00fcttmann A, M\u00fcller S, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas\u2013a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). 2014, 391-391.","DOI":"10.1182\/blood.V124.21.391.391"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0014","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hardy EL, Gill KK, et al. Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). 2014, 392-392.","DOI":"10.1182\/blood.V124.21.392.392"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","article-title":"Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)","volume":"170","author":"Swinnen","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.13036","article-title":"Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial","volume":"167","author":"Pardal","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0018","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3109\/10428194.2013.862242","article-title":"Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma","volume":"55","author":"Stewart","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning","volume":"15","author":"Kasamon","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11307-009-0259-3","article-title":"On the added value of baseline FDG-PET in malignant lymphoma","volume":"12","author":"Quarles van Ufford","year":"2010","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0022","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.22.4089","article-title":"Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials","volume":"27","author":"Meignan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0023","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/annonc\/mdq428","article-title":"Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma","volume":"22","author":"Barrington","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0025","first-page":"1273","article-title":"2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution","volume":"11","author":"Partridge","year":"2000","journal-title":"AnnOncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0026","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0027","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0028","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6601561","article-title":"Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma","volume":"90","author":"Naumann","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0029","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdh426","article-title":"Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease","volume":"15","author":"Munker","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0030","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdj024","article-title":"Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET\/CT era?","volume":"17","author":"Raanani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0032","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","article-title":"Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0033","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: Results from the response-adapted therapy in advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0034","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"(18)F-FDG PET\/CT bone\/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0036","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10428194.2011.616613","article-title":"Routine bone marrow biopsy is not necessary in the staging of patients with classical Hodgkin lymphoma in the 18F-fluoro-2-deoxyglucose positron emission tomography era","volume":"53","author":"Richardson","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0037","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2012.45.5402","article-title":"Hodgkin lymphoma: Protecting the victims of our success","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0038","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2017.09.001","article-title":"PET\/CT for staging; past, present, and future","volume":"48","author":"El-Galaly","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0039","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1148\/radiol.2323030985","article-title":"Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?","volume":"232","author":"Schaefer","year":"2004","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0040","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","article-title":"Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma","volume":"19","author":"Elstrom","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0041","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00259-003-1375-y","article-title":"FDG-PET\/CT in re-staging of patients with lymphoma","volume":"31","author":"Freudenberg","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0042","first-page":"1643","article-title":"PET\/CT in lymphoma: Prospective study of enhanced full-dose PET\/CT versus unenhanced low-dose PET\/CT","volume":"47","author":"Rodr\u00edguez-Vigil","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0043","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/RCT.0000000000000067","article-title":"Can full-dose contrast-enhanced CT be omitted from an FDG-PET\/CT staging examination in newly diagnosed FDG-avid lymphoma?","volume":"38","author":"van Hamersvelt","year":"2014","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0044","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2005.01.904","article-title":"Role of positron emission tomography in lymphoma","volume":"23","author":"Juweid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/asheducation-2006.1.259","article-title":"Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma","volume":"2006","author":"Juweid","year":"2006","journal-title":"Hematology"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0046","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2967\/jnumed.107.046292","article-title":"18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: Where is the evidence?","volume":"49","author":"Juweid","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0047","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1988.6.6.931","article-title":"Residual mass in lymphoma may not be residual disease","volume":"6","author":"Canellos","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0048","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.1988.6.6.940","article-title":"The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease","volume":"6","author":"Radford","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0049","doi-asserted-by":"crossref","first-page":"27 2-8","DOI":"10.1046\/j.1365-2141.2001.03169.x","article-title":"Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?","volume":"115","author":"Spaepen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0050","first-page":"1225","article-title":"Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation","volume":"44","author":"Guay","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0051","first-page":"146","article-title":"18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations [German]","volume":"215","author":"Wickmann","year":"2003","journal-title":"Klin Padiatr"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0052","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1536-1632(03)00107-0","article-title":"Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease","volume":"6","author":"Filmont","year":"2004","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0053","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/1042819031000149430","article-title":"FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison","volume":"45","author":"Friedberg","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0054","first-page":"1209","article-title":"18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results","volume":"14","author":"Rigacci","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0056","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma [published correction appears in J Nucl Med. 2010 Oct;51(10):1658]","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0057","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0058","doi-asserted-by":"crossref","unstructured":"Hutchings M, Kostakoglu L, Zaucha JM, et al. In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for hodgkin lymphoma. J Clin Oncol 32, 2705-2711. https:\/\/doi.org\/10.1200\/JCO.2013.53.2838.","DOI":"10.1200\/JCO.2013.53.2838"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0059","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1093\/annonc\/mdx524","article-title":"The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study","volume":"28","author":"Zaucha","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0060","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0061","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease","volume":"91","author":"Gallamini","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0062","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/annonc\/mdl122","article-title":"Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients","volume":"17","author":"Zinzani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0063","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18F-FDG PET in Hodgkin's lymphoma: Evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0064","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian\u2013Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0065","doi-asserted-by":"crossref","first-page":"17702","DOI":"10.1038\/s41598-022-22032-3","article-title":"Interim FDG-PET\/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma","volume":"12","author":"Al-ibraheem","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0066","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate among Reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0067","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0068","first-page":"104","article-title":"The role of FDG-PET in Hodgkin lymphoma","volume":"21","author":"Subocz","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0069","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 Study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal Function and Fertility in survivors after Hodgkin Lymphoma Treatment within the German Hodgkin Study Group HD13 to HD15 Trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0071","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/cancers13205222","article-title":"FDG-PET\/CT in Lymphoma: Where do we go now?","volume":"13","author":"Al Tabaa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0072","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and difffuse large B-cell lymphoma: a systemic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0073","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: The importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0074","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdq549","article-title":"End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0075","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3109\/10428194.2012.735667","article-title":"Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy","volume":"54","author":"Filippi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0076","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0077","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0078","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.1999.17.8.2493","article-title":"Assessment and significance of mediastinal bulk in Hodgkin's disease: Comparison between computed tomography and chest radiography","volume":"17","author":"Bradley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0079","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0080","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease: International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0081","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin's lymphoma: Diagnosis and treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0082","unstructured":"Hoppe RT, Advani RH, Bierman PJ, et al. NCCN Hodgkin disease clinical practice guidelines in oncology. 2006 v.1. Available at: http:\/\/www.nccn.org. Last Accessed January 6, 2006."},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0083","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0084","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/cncr.20568","article-title":"The clinical value of tumor burden at diagnosis in Hodgkin lymphoma","volume":"101","author":"Gobbi","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0085","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/cas.12282","article-title":"Metabolic tumor volume by positron emission tomography\/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma","volume":"104","author":"Song","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0086","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0087","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1748-717X-7-5","article-title":"Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease","volume":"7","author":"Tseng","year":"2012","journal-title":"Radiat Oncol"},{"issue":"15_suppl","key":"10.1053\/j.semnuclmed.2022.10.006_bib0088","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1200\/jco.2013.31.15_suppl.8555","article-title":"Interim FDG PET\/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL)","volume":"31","author":"Knight-Greenfield","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0089","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1007\/s00330-022-09039-0","article-title":"Utility of pre-treatment FDG PET\/CT-derived machine learning models for outcome prediction in classical Hodgkin lymphoma","volume":"32","author":"Frood","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2967\/jnumed.121.263067","article-title":"The Impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18F-FDG PET scans of patients with classical hodgkin lymphoma","volume":"63","author":"Driessen","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0091","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41598-018-37197-z","article-title":"A PET Radiomics model to predict refractory mediastinal hodgkin lymphoma","volume":"9","author":"Milgrom","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0092","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41824-020-00078-8","article-title":"Methodological framework for radiomics applications in Hodgkin's lymphoma","volume":"4","author":"Sollini","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0093","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40336-021-00451-y","article-title":"The role of 18F-FDG PET\/CT radiomics in lymphoma","volume":"9","author":"Rizzo","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0094","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0095","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0096","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MOH.0000000000000158","article-title":"Targeting immune checkpoints in lymphoma","volume":"22","author":"Ansell","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0097","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cpet.2019.08.011","article-title":"Current Evidence on PET response assessment to immunotherapy in lymphomas","volume":"15","author":"Lopci","year":"2020","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0098","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0099","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","article-title":"Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma","volume":"91","author":"Dercle","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0101","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from lYsa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10428194.2018.1488254","article-title":"18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors","volume":"6","author":"Castello","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0103","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.006_bib0104","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:39:39Z","timestamp":1757543979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822000915"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT in Hodgkin Lymphoma: An Update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}